NanoViricides Total Operating Expenses from 2010 to 2026
| NNVC Stock | USD 0.90 0.05 6.00% |
Total Operating Expenses | First Reported 2005-09-30 | Previous Quarter 2.1 M | Current Value 1.7 M | Quarterly Volatility 899.6 K |
Check NanoViricides financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NanoViricides' main balance sheet or income statement drivers, such as Interest Expense of 179.9 M, Other Operating Expenses of 7.3 M or Research Development of 4.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.96 or PTB Ratio of 2.94. NanoViricides financial statements analysis is a perfect complement when working with NanoViricides Valuation or Volatility modules.
NanoViricides | Total Operating Expenses | Build AI portfolio with NanoViricides Stock |
Analyzing NanoViricides's Total Operating Expenses over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Operating Expenses has evolved provides context for assessing NanoViricides's current valuation and future prospects.
Latest NanoViricides' Total Operating Expenses Growth Pattern
Below is the plot of the Total Operating Expenses of NanoViricides over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. NanoViricides' Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NanoViricides' overall financial position and show how it may be relating to other accounts over time.
| Total Operating Expenses | 10 Years Trend |
|
Total Operating Expenses |
| Timeline |
NanoViricides Total Operating Expenses Regression Statistics
| Arithmetic Mean | 7,950,324 | |
| Geometric Mean | 6,283,996 | |
| Coefficient Of Variation | 29.72 | |
| Mean Deviation | 1,487,570 | |
| Median | 8,659,682 | |
| Standard Deviation | 2,362,597 | |
| Sample Variance | 5.6T | |
| Range | 11M | |
| R-Value | 0.59 | |
| Mean Square Error | 3.9T | |
| R-Squared | 0.34 | |
| Significance | 0.01 | |
| Slope | 274,642 | |
| Total Sum of Squares | 89.3T |
NanoViricides Total Operating Expenses History
About NanoViricides Financial Statements
NanoViricides stakeholders use historical fundamental indicators, such as NanoViricides' Total Operating Expenses, to determine how well the company is positioned to perform in the future. Although NanoViricides investors may analyze each financial statement separately, they are all interrelated. For example, changes in NanoViricides' assets and liabilities are reflected in the revenues and expenses on NanoViricides' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NanoViricides. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Operating Expenses | 11 M | 7.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether NanoViricides offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NanoViricides' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nanoviricides Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nanoviricides Stock:Check out the analysis of NanoViricides Correlation against competitors. For information on how to trade NanoViricides Stock refer to our How to Trade NanoViricides Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Will Biotechnology sector continue expanding? Could NanoViricides diversify its offerings? Factors like these will boost the valuation of NanoViricides. Anticipated expansion of NanoViricides directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NanoViricides data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding NanoViricides requires distinguishing between market price and book value, where the latter reflects NanoViricides's accounting equity. The concept of intrinsic value - what NanoViricides' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push NanoViricides' price substantially above or below its fundamental value.
It's important to distinguish between NanoViricides' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NanoViricides should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NanoViricides' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.